Loyal：单人创始人为狗狗长寿药融资510万美元种子轮

做的是什么生意

Loyal is a biotech company developing drugs to extend dog lifespan and healthspan, an early bet in what its founder calls consumer bio: drug discovery aimed at pet owners who pay out of pocket.

启动资金：$5.1M seed (closed January 2020); ~$6M more by May 2021

起因

Celine Halioua, a neuroscience graduate, former Oxford PhD candidate and two-year VC, was not planning to start a company when a campfire conversation about making dogs live longer reached Greg Rosen, an investor building a pet-genomics thesis. Regular coffees through summer 2019 turned the idea into Loyal (raised under the name Celevity); when Rosen offered a term sheet, she decided to leave her job and go out for her first round.

经过

She raised for an idea and a deck — no co-founder, team or lab data — targeting Silicon Valley and NYC tech and biotech funds while skipping traditional East Coast biotech VCs, whose pre-lead drug deals she considered far more dilutive. After Rosen and Longevity Fund committed about half the round on terms they set together, she ran a CRM of 157 investors, compressed about 65 pitch meetings into six weeks, and 17 investors (roughly 11%) converted; the first 80% of the round subscribed in about two weeks, the last 20% took three, and the round closed oversubscribed at $5.1M in January 2020. She deliberately prioritized speed and partner fit over dilution, iterating an 80-page deck into a ~20-slide main story with a detailed appendix, and later closed roughly another $6M.

可借鉴之处

即使从局外人开始，融资也是可工程化的：将市场CRM化、压缩时间线、迭代推销——并且有意识地用稀释换取速度和合作伙伴契合度。